Imaging genetics of FOXP2 in dyslexia

To cite this version:
Arndt Wilcke, Carolin Ligges, Jana Burkhardt, Michael Alexander, Christiane Wolf, et al.. Imaging genetics of FOXP2 in dyslexia. European Journal of Human Genetics, Nature Publishing Group, 2011, <10.1038/ejhg.2011.160>. <hal-00677000>

HAL Id: hal-00677000
https://hal.archives-ouvertes.fr/hal-00677000
Submitted on 7 Mar 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Imaging genetics of *FOXP2* in dyslexia

Arndt Wilcke§,1,2, Carolin Ligges§,4, Jana Burkhardt1, Michael Alexander5,6, Christiane Wolf2, Elfi Quente1, Peter Ahnert3,10, Per Hoffmann6, Albert Becker8, Bertram Müller-Myhsok7, Sven Cichon5,6,9, Johannes Boltze1,2, Holger Kirsten1,2,3,10

§ Both authors contributed equally to the manuscript and are both considered as first authors.

1 Translational Centre for Regenerative Medicine (TRM), Universität Leipzig, Germany

2 Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany

3 Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Leipzig

4 Department of Child and Adolescent Psychiatry, Friedrich Schiller University, Jena

5 Department of Genomics, Life & Brain Center, University of Bonn, Bonn

6 Institute of Human Genetics, University of Bonn, D-53111 Bonn

7 Max Planck Institute of Psychiatry, RG Statistical Genetics, Munich

8 Department of Neuropathology, University of Bonn Medical Center, Bonn

9 Institute of Neuroscience and Medicine (INM-1), Structural and Functional Organization of the Brain, Genomic Imaging Research Center Juelich, Juelich

10 LIFE Center (Leipzig Interdisciplinary Research Cluster of Genetic Factors, Phenotypes and Environment), Universität Leipzig, Germany
Corresponding author:
Arndt Wilcke, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstr. 1,
04103 Leipzig, Germany, Tel. +49 341 97497, Fax +341 97 25819,

arndt.wilcke@izi.fraunhofer.de

Running title:
FOXP2 as a potential candidate gene for dyslexia
Imaging genetics of *FOXP2* in dyslexia

Abstract

Dyslexia is a developmental disorder characterised by extensive difficulties in the acquisition of reading or spelling. Genetic influence is estimated at 50-70%. However, the link between genetic variants and phenotypic deficits is largely unknown.

Our aim was to investigate a role of genetic variants of *FOXP2*, a prominent speech and language gene, in dyslexia using imaging genetics. This technique combines functional magnetic resonance imaging (fMRI) and genetics to investigate relevance of genetic variants on brain activation. To our knowledge, this represents the first usage of fMRI based imaging genetics in dyslexia.

In an initial case/control study (n=245) for prioritisation of *FOXP2* polymorphisms for later use in imaging genetics, nine SNPs were selected. A non-synonymously coding mutation involved in verbal dyspraxia was also investigated.

SNP rs12533005 showed nominally significant association with dyslexia (genotype GG odds ratio recessive model=2.1 [95% confidence interval 1.1-3.9], p=0.016). A correlated SNP was associated with altered expression of *FOXP2* in vivo in human hippocampal tissue. Therefore, influence of the rs12533005-G risk variant on brain activity was studied. fMRI revealed a significant main effect for the factor “genetic risk” in a temporo-parietal area involved in phonological processing as well as a significant interaction effect between the factors “disorder” and “genetic risk” in activation of inferior frontal brain areas. Hence, our data may hint at a role of *FOXP2* genetic variants in dyslexia specific brain activation and demonstrate use of imaging genetics in dyslexia research.

**Keywords**: dyslexia, imaging genetics, *FOXP2*, fMRI, genetics
**Introduction**

The feasibility to combine functional imaging studies and genetics was demonstrated in several studies\(^1\). Imaging genetics approaches investigate the role of certain genetic variants (e.g. single nucleotide polymorphisms - SNPs) on brain activation independently of indirect measurements like behavioural or neuropsychological testing. Promising results were already shown for other neurological disorders, e.g. in studies of anxiety\(^2\), attentional processes\(^3\) or schizophrenia\(^4\). However, to our knowledge, no functional imaging genetics study has been published on dyslexia so far.

Dyslexia is a specific and severe disorder of reading and spelling, with approximately 5% affected schoolchildren in Germany\(^5\). About 50-70% of dyslexia can be explained by genetic influence\(^6\). However, as all so far identified disease genes account only for a small part of genetic risk, more dyslexia related genes need to be identified. *FOXP2* is a highly relevant candidate gene, situated on chromosome 7q31, close to 7q32, a genomic region in linkage with dyslexia\(^7\). *FOXP2* was discovered to be a central gene in language development\(^8-10\), not limited to humans\(^11-14\). Its functional mechanism could be connected with a downregulation of *CNTNAP2*, a gene implicated in neuronal recognition and cell adhesion\(^15\). *FOXP2*’s role in language originally became apparent by the discovery of a missense mutation (R553H) leading to developmental verbal dyspraxia\(^16\). However, a mutation screen of *FOXP2* in six affected individuals\(^7\) found no specific mutations in dyslexia.

Several functional magnetic resonance imaging (fMRI) studies revealed specific differences between dyslexics and normal readers in reading related brain regions. Consistently, three left hemispheric areas (inferior frontal\(^17\), partly involving Broca’s area, dorsal, and ventral temporal cortices, including Wernicke’s area) showed significant activation differences in dyslexics in phonological tasks\(^18, 19\). The dorsal and
ventral areas show, independently from language\textsuperscript{20}, less activation in dyslexics compared to normal readers. In older dyslexics, the inferior frontal area is often overactivated. However, this overactivation could also be interpreted as a compensational reading strategy\textsuperscript{19}.

The functional effect of a FOXP2 mutation on inferior frontal and supramarginal brain areas has been demonstrated by Liégeois et al. (2003) for silent and spoken language processing\textsuperscript{10}. Therefore our aim was to analyse the role of genetic variants of \textit{FOXP2} in the processing of written language in dyslexia. Thus we combined genetics and fMRI using an imaging genetics approach. To select a possibly functionally relevant \textit{FOXP2} variant, we initially applied a case/control (n=245) study. Relevance of the most promising variant was investigated in respect to potential functional consequences on brain activation in a reading related task in fMRI.

**Materials and methods**

\textit{Ethical approval}

Our study was approved by the ethics committees of the Universities of Leipzig and Jena as well as the Saxon Ministry of Culture and Sports. Informed and written consent was obtained from subjects’ parents.

\textit{Study group for genetic epidemiology}

This group consisted of 61 dyslexics of German origin and 184 healthy, ethnically matched blood donors as controls. Dyslexics were recruited in the 3\textsuperscript{rd} or 4\textsuperscript{th} grade of special Saxonian dyslexia classes. Age was between 8.8 and 11.4 years, 63\% were male. Cases were ascertained in a two-stage approach: First, schools with special dyslexia classes were contacted. Children in those classes were already tested thoroughly at the end of 2nd grade by the local school board with a variety of psychometric tests,
including non-verbal intelligence, letter knowledge, phoneme mergence, spelling, memory, mathematical skills as well as reading and listening comprehension. Pursuant to the admission criteria for the special dyslexia classes only children without memory or math problems and a discrepancy between IQ and reading performance of at least 1.25 standard deviations get access to those classes.

Second, additional tests\textsuperscript{21-23} described elsewhere in detail\textsuperscript{24} were applied to assess reading performance, minimise inclusion of children with attention deficit/hyperactivity (ADD/ADHD) and ensure an IQ $\geq 85$. No siblings or twins were included.

\textit{SNP selection}

We identified tagging SNPs covering common variants with a minor allele frequency (MAF) $\geq 0.1$ (HapMap data release 24, Haploview-Version 4.0 beta 13 and HapMap Public Release #21a,) applying aggressive tagging, an $r^2$ threshold of 0.8, and a logarithm of the odds (LOD) threshold for multi-marker tests of 3.0. Nine SNPs were selected: rs12533005, rs10228350, rs10268637, rs4727799, rs17137124, rs7782412, rs12670585, rs936146, and rs10953766. They covered 87\% of all common HapMap SNPs located in \textit{FOXP2} with a mean $r^2$ of 0.97. Furthermore, we genotyped the mutation R553H, previously found in a large Pakistani family with severe speech and language disorder\textsuperscript{8}.

\textit{Genotyping and genetic analysis}

DNA extraction and PCR primer design were done as described\textsuperscript{24}. Primers for single base extension (SBE) including photo-cleavable sites\textsuperscript{25} were designed using CalcDalton\textsuperscript{26}. SNPs were genotyped applying the method “GenoSNIP” as described previously\textsuperscript{25,27}. Primer sequences are shown in Supplemental table I.
Genetic statistics

We analysed SNPs for association with dyslexia applying $\chi^2$ statistics in allelic, dominant, and recessive models as well as applying the Cochran-Armitage test. SNPs of cases and of controls were in Hardy-Weinberg Equilibrium (HWE) ($p>0.05$) indicating no major genotyping errors. Average genotyping rate was 98% for cases and controls. Haploview 4.1 was used to test for haplotype association for haplotypes with a frequency $>5\%$. P-values are shown without correction for multiple testing. The study was powered to detect a difference of at least 15% in the minor allele frequencies (MAF) of selected SNPs between cases and controls translating to a minimum detectable odds ratio (OR) of 1.85 28.

Prediction of altered gene expression in silico

MatInspector and Genomatix software suite (NCBI 37, ElDorado 12-2010), were used to investigate possible loss/gain of transcription factor (TF) binding sites as described elsewhere29. Minimum core similarity (score of the highest conserved positions of a matrix match) was 1.00.

Analysis of differential allelic gene expression in human hippocampus

Biopsy samples (n=142) were obtained from patients with chronic pharmacoresistant temporal lobe epilepsy. After quality control, 138 individuals were included in subsequent analyses (63 male, mean age 31.72 years, standard deviation SD=16.27, age range newborn to 64 years). Fresh frozen human hippocampal segments were prepared as tissue-slices under cryostat-conditions (Bonn tissue bank). Total DNA and RNA were isolated using the AllPrep DNA/RNA Micro Kit (Qiagen, Hilden, Germany). Quality of total RNA of all samples was checked for degradation (RNA integrity number RIN>7.9) via BioAnalyzer measurements (Agilent Technologies, Waldbronn,
Germany). 50 ng of total RNA were amplified (Illumina TotalPrep 96-RNA Amplification Kit, Ambion/Applied Biosystems, Darmstadt, Germany). Labelled cRNA was hybridised to Illumina human HT-12 Expression v3 BeadChips (Illumina, San Diego, USA). All expression profiles were extracted using GenomeStudio software (Illumina, San Diego, USA). For genome-wide SNP-genotyping 200 ng of DNA was hybridised to the Illumina Human660W-Quad v1 DNA Analysis BeadChip (Infinium® HD Assay Super manual, Illumina). Individuals were excluded if their position differed more than 6 standard deviations from the mean position on at least one of the first two axes of the multi-dimensional scaling analysis on the identical by state matrix of genotyped SNPs. Quality thresholds were: HWE p-value $\geq 1 \times 10^{-5}$, MAF $\geq 1\%$, individual callrate $\geq 98\%$, SNP callrate $\geq 98\%$ and a false discovery rate of 1% for autosomal heterozygosity. Average genotyping rate was 98%. The sequences of expression probes were re-aligned to UC SC version 18 (hg18) allowing only perfect matches. Probes containing either intrinsic polymorphisms or matching to multiple positions in the human genome were excluded from downstream analysis. Remaining probes were normalised using the vsn2 option implemented in the package “VSN” for R. For quantitative trait analysis linear regression of an additive allelic model was performed using the GenABEL package for R. Covariates included in the model were gender and age at sampling. To take population stratification into account, we also included the first five components resulting from multidimensional scaling analysis.

For the investigation of the SNP’s potential influence on FOXP2 expression, we had to use proxy SNPs since rs12533005 was not included on the Illumina Human660-W Quad array. We identified proxy SNPs by filtering variants correlated with rs12533005 with $r^2 > 0.5$ according to HapMap release 22 (International HapMap Project
http://www.hapmap.org), and an additionally effect on gene expression of \textit{FOXP2}-probes with a nominal p-value $\leq 0.05$. Out of five resulting SNPs, we report data of the variant with strongest effect size (rs10249531).

\textit{Study group for fMRI investigation}

In an additional, independent sample we investigated children with fMRI. The sample consisted of 19 dyslexics (12 male, mean age 11.46 years, standard deviation SD=1.04) and 14 controls (11 male, mean age 11.56, SD=0.73). Dyslexics and controls were recruited in Thuringia, a German federal state adjacent to Saxony. Inclusion criteria were a IQ $\geq 85$ (nonverbal part of HAWIK-III\textsuperscript{30}), right handedness\textsuperscript{31}, no attention deficit disorder\textsuperscript{21,31}, and no history of neurological or psychiatric disorders. Diagnosis of dyslexia was based upon two criteria: (a) discrepancy between nonverbal IQ and reading\textsuperscript{32}/spelling\textsuperscript{33-36} $\geq 1.5$ standard deviations and (b) reading/spelling performance (transformed to IQ-scale) $< 85$. Normal performance of controls was controlled by reading/spelling performance (transformed to IQ-scale) $> 85$. Controls were matched to dyslexics according to nonverbal IQ and age. Both groups did not differ significantly in IQ and age. In accordance with the additive model applied in differential allelic gene expression analysis, carriers of allele rs12533005-G were classified as subjects with genetic risk, individuals homozygous for rs12533005-C as subjects without genetic risk.

\textit{fMRI paradigm}

fMRI data were acquired in a Siemens Magnetom Vision 1.5 Tesla MRI Scanner (Erlangen, Germany) using a T2-weighted epi-sequence (TE=60 ms, TR=0.6 ms, TA=3496 ms, FOV=192 mm, FA=90°, 64x64 matrix) with 32 slices (4 mm slice thickness).
To operationalise phonological as well as low level visual processing we used a paradigm comprising (1) phonological stimuli (“rhyming”: do the names of two letters rhyme; e. g. “G” and “T”) and (2) visual control stimuli (“slashes”: are two slashes inclined in the same direction; e. g. “\)” vs. “\”).

The experiment was conducted in a block design. Four scans were acquired per block. For each stimulus type, 11 blocks were acquired, totalling 44 scans per task. Each stimulus block was followed by a baseline-task-block (“fixation”: fixation cross for 13984 ms, 21 baseline blocks in total with 4 scans per block). The block sequence was kept the same between subjects.

Subjects had to indicate their decision via button press, allowing the acquisition of reaction time and error rate (Presentation, Neurobehavioral Systems, http://www.neurobs.com/presentation). The trial setup was fixed to a duration of 3000 ms followed by a 450 ms inter stimulus interval. During each trial the stimuli were presented for a maximum of 3000 ms. The stimulus disappeared after the button press, leaving a blank screen until the end of the 3000 ms interval.

**fMRI data analysis**

fMRI data were analysed with the SPM8 package (Institute of Neurology, London, UK, http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). Spatial pre-processing included: (a) realignment of all functional images to the session’s first image and computation of a mean image out of realigned images, (b) normalisation of realigned functional images to the EPI-MNI-template (International Consortium for Brain Mapping template, Montreal Neurological Institute, Montreal, Canada) by estimation of normalisation parameters for the mean image and their application to functional images and (c) smoothing of images with a Gaussian kernel of 9 mm FWHM.
First-level analyses were computed for each subject using a voxel-by-voxel-t-test for the contrasts of (A) rhyming vs. fixation as well as (B) rhyming vs. slashes. Second-level analyses for the contrasts (A) and (B) were computed via 2 x 2 analysis of variance (ANOVA) with factors “disorder” (dyslexic or normal reader) and “genetic risk” (risk variant rs12533005-G or no risk variant) using a full factorial design. Post-hoc t-tests were done to test intergroup-effects for (1) controls vs. dyslexics, (2) dyslexics vs. controls, (3) no-risk subjects vs. risk subjects, (4) risk subjects vs. no-risk subjects. fMRI results are reported on an uncorrected p-level of 0.001 and a cluster level of 10.

Results

Selection of genetic variants for imaging analysis

The following SNPs in *FOXP2* were investigated for association with dyslexia: rs12533005 and rs10228350 (intron 1), rs10268637 and rs4727799 (intron 2), rs17137124 (intron 3), rs7782412 and rs12670585 (intron 9), rs936146 (intron 11), rs10953766 (intron 17) and their resulting haplotypes. We also studied the R553H mutation described by Lai et al. A summary including the linkage disequilibrium (LD) structure of *FOXP2* in our population is shown in Supplemental figure I.

SNP rs12533005 showed nominal significant association (odds ratio genotype G/G, recessive model: 2.1 [95% confidence interval 1.1-3.9] p=0.016; Cochran-Armitage test p=0.049, for more details see Supplemental table II). No effect of age on allele frequency as described elsewhere was found. Other tested SNPs and haplotypes did not show significant frequency differences between cases and controls (Supplemental tables II and III). None of the haplotypes showed stronger association than single marker rs12533005. No sex specific differences were observed. Haplotype structure in our cohort was comparable to that in HapMap CEU panel. Mutation R553H was not
present in any cases or controls. Hence, we selected rs12533005 for further imaging genetic analyses.

Prediction of altered gene expression in silico

Three TF-binding sites for regulators ATBF1 (=ZFHX3), LEF1, and MEL1 (=PRDM16) are predicted in silico to be present for carriers of the risk variant rs12533005-G, but not for rs12533005-C. Matrix similarity (score of the complete matrix match) for ATBF1, LEF1, and MEL1 was 0.80, 0.86, and 1.00, respectively.

Analysis of differential allelic gene expression in human hippocampus

As rs12533005 was not originally included in the analysis of differential allelic expression in human hippocampus, we identified rs10249531 located 41 kb upstream of rs12533005 as most relevant proxy ($r^2=0.6$, $D'=1.0$). SNP rs10249531-C (correlating with rs12533005-G) was nominally associated with decreased FOXP2 expression ($p=0.018$), accounting for 4.1 % of gene expression variability (Supplemental figure II). Within the additive model representing the effect of rs10249531-C on FOXP2 gene expression levels, we found a regression coefficient beta of -0.024. Within our sample, there was no evidence for age-dependent expression differences.

fMRI results

Among analysed SNPs of FOXP2, rs12533005 showed the strongest signs of association with dyslexia. Therefore, the functional relevance of this SNP in language and speech processing was further analysed using fMRI.

Intragroup results

Individuals of the fMRI-sample were grouped according to disorder state: (1) dyslexics (n=19), (2) controls (n=14); and according to carriage of rs12533005-G: (3) subjects
with genetic risk (n=25), (4) subjects without genetic risk (i.e. individuals homozygous for rs12533005-C, n=8). Intragroup results for the contrast (A) rhyming vs. fixation for groups (1) and (2) showed in each group activations in the expected (phonological) reading network comprising occipital and inferior temporal brain areas, the angular gyrus, the insula and inferior frontal brain areas (Figure 1). The same areas were found to be activated when groups were defined according to (3) and (4). For contrast (B), rhyming vs. slashes, activity in the same network could be observed.

Main effects and interactions

In contrast (A) there was only a single cluster of right middle frontal brain areas associated with the main effect “disorder”. For main effect “genetic risk” there was an association in a superior temporal cluster bordering to the angular gyrus. For the interaction effect “disorder x genetic risk” a left sided cluster in the Rolandic operculum could be observed.

In contrast (B) there were three clusters associated with the main effect “disorder”: one left sided cluster in the white matter close to the insula, one cluster in the gray matter close to the anterior commissure and the third in the right cerebellum. For the main effect “genetic risk” various small clusters within the right precuneus, the left and right nucleus caudatus, right-sided superior frontal, the left and right temporal pole, left-sided postcentral, and, finally, in the left-sided fusiform gyrus could be observed. For the interaction effect “disorder” x “genetic risk” clusters in the left and right precuneus as well as in the right superior medial gyrus could be observed. Main effects and interactions for contrasts (A) and (B) are depicted in Figure 2.

Post-hoc t-tests
Post-hoc t-tests were applied to investigate the direction of main effects and interactions. The post-hoc t-tests for the contrast (A) for controls vs. dyslexics revealed no significant effects, whereas the t-test for dyslexics vs. controls showed a small overactivation in the right-sided fusiform gyrus. The t-test of no genetic risk vs. genetic risk (i.e. non-carriage vs. carriage of rs12533005-G) showed a prominent overactivation in the supramarginal and angular gyri as well as three small clusters of overactivation in (I) an area bordering on the inferior frontal gyrus, (II) the superior occipital gyrus and (III) the lingual gyrus for subjects with no genetic risk. The t-test of genetic risk vs. no genetic risk did not show any significant effects.

Post-hoc t-tests for contrast (B) for controls vs. dyslexics showed two clusters in the white matter left and right middle frontal, the t-test for dyslexics vs. controls showed two small clusters left-sided in the lingual, fusiform, and middle occipital gyrus. The t-tests for non-genetic risk vs. genetic risk and vice versa showed no significant clusters.

**Discussion**

Imaging genetics links genetic variants and their functional relevance in brain activation. To our knowledge we report for the first time results of imaging genetics in dyslexia. We initially performed a genetic association analysis of *FOXP2* variants to prioritise markers for use in fMRI analysis. We selected *FOXP2* tagging SNPs and the coding variant R553H, a mutation initially found to be associated with severe speech and language disorder in a Pakistani family by Lai et al.\(^8\). No other coding variants of *FOXP2* were investigated as no non-synonymously coding SNPs were reported in dbSNP (Build 130) and no non-synonymously coding SNPs in *FOXP2* were found in dyslexics in a previous study\(^7\). The coding mutation R553H was not found in any individual in our study, strengthening the hypothesis that R553H is a rare mutation.
present only in some sparse families and not of relevance for diseases in the general population\textsuperscript{38}. Of studied variants, only SNP rs12533005 showed nominal significant association with dyslexia (p=0.016). As \textit{FOXP2} haplotypes did not show stronger association than single marker rs12533005, this variant was chosen for imaging genetics analysis.

Since rs12533005 is an intronic SNP, it does not change the protein sequence of \textit{FOXP2}. It may be a marker for a yet unknown functional variant or it may modify regulation of gene expression. Notably, according to the PupaSuite database\textsuperscript{39}, rs12533005 is classified to be situated in a conserved region. Three TF-binding sites (ATBF1, LEF1, and MEL1) are predicted to be present in carriers of risk variant rs12533005-G, but not for rs12533005-C. MEL1 and ATBF1 play a role in regulatory transcription processes in the mammalian central nervous system\textsuperscript{40}. Positive MEL1 regulation indicates a multistep regulatory network aimed at expression of specific neuronal repressors\textsuperscript{41}. ATBF1 acts as repressor of gene expression by down-regulating AT-rich enhancer elements\textsuperscript{42,43} and LEF1 seems to be involved especially in downregulation of E-cadherin, which is important for cellular polarity and adhesion processes during embryonic development in general\textsuperscript{44} as well as embryonic brain morphogenesis\textsuperscript{45}.

To verify the results of our \textit{in silico} analysis we examined differential allelic expression of \textit{FOXP2} rs12533005 in 138 human resected hippocampi. In this dataset, the most relevant proxy for rs12533005 – which was not contained on the Illumina SNP array used by us - was rs10249531. We found significant reduction of \textit{FOXP2} gene expression for rs10249531-C, which is associated with rs12533005-G (Supplemental figure II). While there is no perfect linkage disequilibrium between the two SNPs, our data suggest differential allelic expression of \textit{FOXP2} depending on rs12533005 alleles.
This supports our *in silico* prediction for a repressor binding site generated by rs12533005. We note that hippocampal tissues were derived from epileptic patients. However, we believe that the identified differential allelic expression of FOXP2 is not connected to a specific epilepsy-related process as neither the FOXP2 locus nor FOXP2 expression levels are reported to be associated with epilepsy. Based on these promising data we examined the role of rs12533005 in reading related brain activation.

Using fMRI we found for the contrast of the “rhyming” vs. “fixation” task a significant main effect of activation difference for the factor “risk” (i.e. comparison of subjects being carriers and non-carriers of the risk variant rs12533005-G). Subsequent one-tailed post-hoc t-tests indicate that the main effect for the factor “risk” can be explained by an overactivation of the non-carriers of the risk-variant in two temporo-parietal brain areas: the angular and the supramarginal gyrus. This finding is in line with former fMRI research. The angular as well as the supramarginal gyrus are significantly involved in phonological language processing and showed a higher activation in normal readers compared to dyslexics. Thus our observation is consistent with the interpretation that these temporo-parietal brain areas show a functional deficit in carriers of the putative risk variant compared with non-carriers. Therefore our results point to a possible role of SNP rs12533005 in reading related brain activation in the dorsal temporal cortex.

The interaction of factors “disorder” x “genetic risk” showed significant activation differences in the Rolandic operculum, a brain region strongly involved in motoric speech production. Post-hoc t-tests revealed for the comparison of non-risk carriers vs. risk carriers a small cluster of overactivations in an area next to the inferior frontal gyrus. The interaction effect “disorder” x “genetic risk” can probably be explained by stronger activation of non-risk carriers in these inferior frontal areas. This result is in line with earlier findings of an effect of a *FOXP2* mutation on the function of inferior
frontal brain areas\textsuperscript{10}. Yet, due to the incomplete overlap of the cluster localisation between interaction effect and the post-hoc t-test result, our findings from interaction analysis may require further investigation.

Based on our results, it could be speculated that in presence of the risk variant rs12533005-G repressor binding sites are created, leading to decreased \textit{FOXP2} expression. As very tightly regulated \textit{FOXP2} expression in the developing brain seems to be required for development of speech and linguistic functions\textsuperscript{46}, repression might result in neuronal dysfunction giving a possible explanation for our fMRI findings.

We aimed to increase power to detect true positives by integrating genetic and functional data. Yet, given the only moderate sample sizes of the studied populations and no multiple testing correction, our findings need replication.

Our results hint on a possible role of \textit{FOXP2} variants in German dyslexics. The functional link may be found in \textit{FOXP2} influencing function of a left hemispheric brain area involved in spoken (phonological memory) as well as written language (grapheme-phoneme correspondence and the mental lexicon).

While replication of our results in an independent, larger cohort is definitely needed, our results further corroborate the role of \textit{FOXP2} in speech and language development, hint on the relevance of genetic variants of \textit{FOXP2} for reading and spelling, and demonstrate the application of imaging genetics in the investigation of dyslexia.

\textbf{Conflict of Interest}

The authors declare no conflict of interest.

\textbf{Acknowledgements}
The work presented in this paper was made possible by funding from the German Federal Ministry of Education and Research (BMBF, PtJ-Bio, 0315883) to AW and HK, 01KN0702 to PA, and 01GS08144 to SC and AB, the Interdisciplinary Center for Clinical Research Jena (T.P. 1.2/B 307-04004) and a habilitation grant from the Hochschul- und Wissenschaftsprogramm/Thuringia (personal grant for CL). HK and PA were funded by means of the European Union, by the European Regional Development Fund (ERFD), the European Social Fund and by means of the Free State of Saxony (LIFE Center, University of Leipzig).

We thank Nazanin Karbalai for statistical support.

Reference List


11 Fee MS, Scharff C: The songbird as a model for the generation and learning of complex sequential behaviors. *ILAR J* 2010; **51**: 362-377.

12 Fisher SE, Scharff C: FOXP2 as a molecular window into speech and language. *Trends Genet* 2009; **25**: 166-177.


**Titles and legends to figures**

**Figure 1**

**Intragroup results according to state of disorder and genetic risk**

A) Intragroup results for the contrast rhyming vs. fixation, B) Intragroup results for the contrast rhyming vs. slashes. Sample sizes: dyslexics n=19, controls n=14, risk (carriers of rs12533005-G), n=25, no risk (non-carriers of rs12533005-G), n=8.
Main effects and interactions according to state of disorder and genetic risk

A) Results of the F-Test for the contrast rhyming vs. fixation, B) Results of the F-Test for the contrast rhyming vs. letters. Disorder: contrast dyslexics vs. controls. Risk: contrast carriers of rs12533005-G vs. non-carriers. Sample sizes: dyslexics n=19, controls n=14, risk (carriers of rs12533005-G), n=25, no risk (non-carriers of rs12533005-G), n=8.

Supplemental Figure I

Schematic view of FOXP2 and its haplotype structure

Horizontal lines indicate intronic regions, vertical blue lines exonic regions. Long red lines stand for SNPs studied. 1 rs12533005  2 rs10228350  3 rs10268637  4 rs4727799  5 rs17137124  6 rs7782412  7 rs12670585  8 rs936146  9 rs10953766.

Numbers in squared fields indicate correlation between SNP within the haplotype-structure. The SNPs mentioned above cover the region Chr.7:114.055.805-114.312.968 (coordinates according to hg19).

Supplemental Figure II

Differential allelic expression analysis of FOXP2 based on rs10249531

Differential allelic expression data in hippocampal tissue for rs10249531 (representing the most relevant proxy for rs12533005) and ILMN_1695355 (the corresponding transcript on the Illumina Human Whole Genome chipset at position FOXP2 on chromosome 7 at 114.304.471Mb mapping the last and second last exon at the 3’ end), detecting expression of FOXP2.
Supplemental Table I

Overview of studied SNPs and their primer sequences

Supplemental Table II

Detailed overview of genetic results for studied SNPs

OR = odds ratio; OR [95%CI] = Odds ratio [95% confidence interval]

Supplemental Table III

Overview of haplotypes identified by studied SNPs

SNPs in haplotypes are shown in the following order: rs12533005, rs10228350, rs10268637, rs4727799, rs17137124, rs7782412, rs12670585, rs936146, rs10953766.
Intragroup

A) rhyming vs. fixation
- Controls
- Dyslexics
- Risk
- No Risk

B) rhyming vs. slashes
- Controls
- Dyslexics
- Risk
- No Risk

Figure 1 Intragroup results according to disorder state and genetic state
Figure 2 Main effects and interactions according to disorder state and genetic state
Supplemental figure I Schematic view of FOXP2 and its haplotype structure
Supplemental figure II: Differential allelic expression analysis of FOXP2 based on rs10249531
<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP rs Number</th>
<th>SNP-Number</th>
<th>SNP-Type</th>
<th>PCR-Primer 5’</th>
<th>PCR-Primer 3’</th>
<th>SBE-Primer</th>
<th>expected PCR-Product size</th>
</tr>
</thead>
</table>
| FOXP2  | rs12533005    | C/G        |          | ACGTTGGATGGTATTATTATTATATTATTATATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTATTAT

Supplemental table I Overview of studied SNPs and their primer sequences
<table>
<thead>
<tr>
<th>SNP</th>
<th>Case minor genotypes</th>
<th>Case heterozygote genotypes</th>
<th>Case major genotypes</th>
<th>Control minor genotypes</th>
<th>Control heterozygote genotypes</th>
<th>Control major genotypes</th>
<th>OR [95%CI]</th>
<th>p-value allelic OR</th>
<th>OR major allele dominant model [95%CI]</th>
<th>p-value dominant OR</th>
<th>OR major allele recessive model [95%CI]</th>
<th>p-value recessive OR</th>
<th>Cochran-Armitage test p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs12533005</td>
<td>C (16.4%)</td>
<td>T (14.5%)</td>
<td>T (23%)</td>
<td>G (13.3%)</td>
<td>A (14.6%)</td>
<td>A (16.4%)</td>
<td>1.52 [1.0-2.3]</td>
<td>0.52</td>
<td>1.28 [0.60-2.77]</td>
<td>0.528</td>
<td>2.10 [1.15-3.85]</td>
<td>0.016</td>
<td>0.049</td>
</tr>
<tr>
<td>rs10228350</td>
<td>T</td>
<td>G (13.3%)</td>
<td>G (24.6%)</td>
<td>A (8.2%)</td>
<td>G (13.3%)</td>
<td>5 (13.3%)</td>
<td>1.37 [0.7-2.1]</td>
<td>0.811</td>
<td>0.815 [0.44-2.47]</td>
<td>0.952</td>
<td>0.58 [0.58-2.06]</td>
<td>0.016</td>
<td>0.049</td>
</tr>
<tr>
<td>rs10268637</td>
<td>C</td>
<td>T (23%)</td>
<td>T (36.7%)</td>
<td>C (52.5%)</td>
<td>A (39.3%)</td>
<td>G (61.7%)</td>
<td>25 (41%)</td>
<td>0.289</td>
<td>0.64 [0.31-1.30]</td>
<td>0.657</td>
<td>0.85 [0.91-2.93]</td>
<td>0.103</td>
<td>0.87</td>
</tr>
<tr>
<td>rs4727799</td>
<td>G</td>
<td>A (13.3%)</td>
<td>A (19.4%)</td>
<td>T (24.6%)</td>
<td>G (13.3%)</td>
<td>C (52.5%)</td>
<td>22 (43.9%)</td>
<td>0.158</td>
<td>1.37 [0.52-2.83]</td>
<td>1.22</td>
<td>1.65 [0.63-2.31]</td>
<td>0.016</td>
<td>0.016</td>
</tr>
<tr>
<td>rs17137124</td>
<td>A</td>
<td>G (8.2%)</td>
<td>A (24.6%)</td>
<td>C (39.3%)</td>
<td>A (61.7%)</td>
<td>C (52.5%)</td>
<td>25 (41%)</td>
<td>0.827</td>
<td>0.827 [0.46-1.86]</td>
<td>0.93</td>
<td>0.71 [0.36-1.37]</td>
<td>0.87</td>
<td>0.87</td>
</tr>
<tr>
<td>rs7782412</td>
<td>C</td>
<td>A (8.2%)</td>
<td>T (39.3%)</td>
<td>C (61.7%)</td>
<td>G (52.5%)</td>
<td>G (61.7%)</td>
<td>10 (16.4%)</td>
<td>0.821</td>
<td>1.05 [0.68-3.15]</td>
<td>0.821</td>
<td>1.00 [0.56-1.79]</td>
<td>0.016</td>
<td>0.016</td>
</tr>
<tr>
<td>rs12670585</td>
<td>A</td>
<td>G (13.3%)</td>
<td>G (39.3%)</td>
<td>A (52.5%)</td>
<td>A (61.7%)</td>
<td>A (52.5%)</td>
<td>8 (13.1%)</td>
<td>0.984</td>
<td>1.05 [0.38-3.06]</td>
<td>0.984</td>
<td>0.30 [0.86-4.46]</td>
<td>0.016</td>
<td>0.016</td>
</tr>
<tr>
<td>rs936146</td>
<td>G</td>
<td>C (8.2%)</td>
<td>T (39.3%)</td>
<td>C (61.7%)</td>
<td>G (52.5%)</td>
<td>C (61.7%)</td>
<td>8 (13.1%)</td>
<td>0.792</td>
<td>1.05 [0.38-3.06]</td>
<td>0.984</td>
<td>0.30 [0.86-4.46]</td>
<td>0.016</td>
<td>0.016</td>
</tr>
<tr>
<td>rs10953766</td>
<td>A</td>
<td>C (8.2%)</td>
<td>A (39.3%)</td>
<td>C (61.7%)</td>
<td>A (52.5%)</td>
<td>A (61.7%)</td>
<td>8 (13.1%)</td>
<td>0.792</td>
<td>1.05 [0.38-3.06]</td>
<td>0.984</td>
<td>0.30 [0.86-4.46]</td>
<td>0.016</td>
<td>0.016</td>
</tr>
</tbody>
</table>

Supplemental table II Detailed overview of the genetic results for the studied SNPs
OR = Odds ratio, OR [95%CI] = Odds ratio [95% confidence interval]
<table>
<thead>
<tr>
<th>Haplotype</th>
<th>Case-Control-frequencies</th>
<th>Chi-Square</th>
<th>p-value (uncorrected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CACGACGGA</td>
<td>0.198, 0.237</td>
<td>0.8</td>
<td>0.371</td>
</tr>
<tr>
<td>GTTAGTACG</td>
<td>0.198, 0.191</td>
<td>0.031</td>
<td>0.8612</td>
</tr>
<tr>
<td>GTTAGTGGA</td>
<td>0.032, 0.066</td>
<td>1.92</td>
<td>0.1659</td>
</tr>
<tr>
<td>GTTAGCGCG</td>
<td>0.074, 0.047</td>
<td>1.325</td>
<td>0.2498</td>
</tr>
<tr>
<td>GACAATGGG</td>
<td>0.038, 0.050</td>
<td>0.271</td>
<td>0.6027</td>
</tr>
<tr>
<td>CACGACGCG</td>
<td>0.035, 0.036</td>
<td>0.003</td>
<td>0.9534</td>
</tr>
<tr>
<td>GTTAGTGCG</td>
<td>0.034, 0.035</td>
<td>0.004</td>
<td>0.9466</td>
</tr>
<tr>
<td>CACAGTGGA</td>
<td>0.017, 0.033</td>
<td>0.866</td>
<td>0.3522</td>
</tr>
<tr>
<td>GACAACGGA</td>
<td>0.049, 0.020</td>
<td>2.759</td>
<td>0.0967</td>
</tr>
<tr>
<td>GATAGTGCG</td>
<td>0.038, 0.021</td>
<td>1.108</td>
<td>0.2924</td>
</tr>
<tr>
<td>CACGGTGCG</td>
<td>0.008, 0.029</td>
<td>1.688</td>
<td>0.1938</td>
</tr>
<tr>
<td>CACGACGGG</td>
<td>0.028, 0.021</td>
<td>0.255</td>
<td>0.6135</td>
</tr>
<tr>
<td>GACAATGGA</td>
<td>0.013, 0.023</td>
<td>0.4</td>
<td>0.527</td>
</tr>
<tr>
<td>CACAGTACG</td>
<td>0.002, 0.026</td>
<td>2.819</td>
<td>0.0932</td>
</tr>
<tr>
<td>CACGACACG</td>
<td>0.016, 0.021</td>
<td>0.102</td>
<td>0.7491</td>
</tr>
<tr>
<td>GTTAGTAGA</td>
<td>0.037, 0.012</td>
<td>2.963</td>
<td>0.0852</td>
</tr>
<tr>
<td>CACATCGG</td>
<td>0.034, 0.011</td>
<td>2.887</td>
<td>0.0893</td>
</tr>
<tr>
<td>GTTAGTGGG</td>
<td>0.025, 0.009</td>
<td>1.742</td>
<td>0.1869</td>
</tr>
</tbody>
</table>

Supplemental Table III Overview of haplotypes identified by studied SNPs